XNZE
AFT
Market cap188mUSD
Nov 13, Last price
3.20NZD
Name
AFT Pharmaceuticals Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categories, including but not limited to allergy relief, cold and flu remedies, digestive health, eye care, first aid essentials, nail and oral care, pain management, skincare solutions, and nutritional supplements. This company was established in 1997 and its main office is located in Auckland, New Zealand.
Key people
David Flacks
Independent Non-Executive Chairman of the Board · since 2015
Marree Atkinson
Co-Founder, Executive Director, Chief of Staff · since 2012
Simon Bosley
Chief Financial Officer · since 2026
Scott Crawford
General Manager - Promoted Products · since 2022
Hartley Atkinson
Chief Executive Officer, Co-Founder, Managing Director, Executive Director · since 1997
Louise Clayton
Director - International Business · since 2017
Vladimir Ilievski
Regulatory Affairs Manager
Murray Keith
Group Marketing Manager
Ioana Stanescu
Head - Drug Development · since 2012
Andrew Hamish Lane
Non-Executive Independent Director · since 2023
Ted Witek
Non-Executive Independent Director · since 2020
Allison Yorston
Non-Executive Independent Director · since 2024
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||